Simulated human tissue fluid, its preparation method and application

By preparing a simulated human tissue fluid containing water, ionic inorganic salts, albumin, lipids, and nonionic surfactants, the problems of high cost and poor stability of existing simulated human tissue fluids have been solved, enabling electromagnetic radiation testing in the 10GHz–30GHz frequency band and meeting the requirements for frequency band coverage and stability.

CN120741086BActive Publication Date: 2026-06-09HONOR DEVICE CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411021397.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2026-06-09
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

Existing simulated human body fluids are expensive and unstable, and cannot cover electromagnetic radiation testing in the 10GHz to 30GHz frequency band, making it impossible to assess the impact of this frequency band on human health.

Method used

A simulated human tissue fluid was prepared by combining water, ionic inorganic salts, albumin, lipids, nonionic surfactants and preservatives to simulate the electrical properties of skin, and it is suitable for APD testing in the 10GHz to 30GHz frequency band.

Benefits of technology

APD testing was achieved in the 10GHz to 30GHz frequency band, simulating good stability and low cost of skin tissue fluid, thus meeting the frequency band coverage requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120741086B_ABST
    Figure CN120741086B_ABST
Patent Text Reader

Abstract

The application provides a kind of simulated human tissue fluid and its preparation method and application, it relates to wireless communication technical field, the simulated human tissue fluid includes: water, 55wt%~75wt% by mass percentage;Ionic inorganic salt, 2wt%~5wt%;Albumin, 10wt%~18wt%;Lipid, 12wt%~20wt%;Non-ionic surfactant, 2wt%~4wt%;Preservative, 0.2wt%~1wt%.Therefore, by water, ionic inorganic salt, albumin, lipid, non-ionic surfactant and preservative cooperate to simulate the skin of human body, so as to be able to carry out APD test in the frequency range of 10GHz~30GHz, and the stability of simulated skin tissue fluid is good, and the cost is lower.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of wireless communication technology, and in particular to a simulated human tissue fluid, its preparation method, and its application. Background Technology

[0002] With the development of technology, mobile phones, computers and other electronic devices are being used more and more frequently in people's work and life. While enjoying the convenience brought by electronic devices, people are also paying more and more attention to the impact of electromagnetic radiation generated by these electronic devices on human health.

[0003] The relevant technology uses simulated human body fluids to simulate the electrical characteristics of the human body under different frequencies, temperatures, and humidity conditions. Then, by testing the simulated human body fluids, the absorption of electromagnetic radiation by different parts of the human body can be determined.

[0004] However, the purchase cost of commercially available human body simulated liquids is usually quite expensive, and most of the purchased liquids have poor long-term stability. In addition, there are currently no human body simulated liquids in the 10GHz to 30GHz range, which makes it impossible to know the impact of electromagnetic radiation in the 10GHz to 30GHz range on human health. Summary of the Invention

[0005] This application provides a simulated human tissue fluid, its preparation method, and its application. The simulated human skin is achieved by combining water, ionic inorganic salts, albumin, lipids, nonionic surfactants, and preservatives. This allows for APD testing in the frequency range of 10GHz to 30GHz, and the simulated skin tissue fluid exhibits good stability and low cost.

[0006] To achieve the above objectives, this application adopts the following technical solution:

[0007] In a first aspect, a simulated human tissue fluid is provided, comprising, by mass percentage: water, 55wt% to 75wt%; ionic inorganic salts, 2wt% to 5wt%; albumin, 10wt% to 18wt%; lipids, 12wt% to 20wt%; nonionic surfactants, 2wt% to 4wt%; and preservatives, 0.2wt% to 1wt%.

[0008] This application provides a simulated human tissue fluid that, through the combination of water, ionic inorganic salts, albumin, lipids, nonionic surfactants, and preservatives, accurately simulates human skin. This allows for APD testing in the frequency range of 10GHz to 30GHz. Furthermore, the simulated skin tissue fluid exhibits good stability and low cost, which facilitates its wider application.

[0009] In one possible implementation of the first aspect, the lipids include at least unsaturated triglycerides, wherein the percentage content of unsaturated triglycerides in the lipids is greater than or equal to 90%.

[0010] In this implementation, a large amount of unsaturated triglycerides that are liquid at room temperature are added to synthesize the desired liquid simulated skin tissue fluid.

[0011] In one possible implementation of the first aspect, when the percentage content of unsaturated triglycerides in the lipids is less than 100%, the lipids also include at least one of oils, sterols and phospholipids.

[0012] In this implementation, the formulation of simulated human tissue fluid can be enriched, and different simulated human tissue fluids that mimic human skin can be obtained.

[0013] In one possible implementation of the first aspect, the water includes deionized water.

[0014] In this implementation method, deionized water contains fewer ionic impurities and has a neutral pH value, which can minimize the occurrence of impurities or pH affecting the solubility of solutes during solution preparation.

[0015] In one possible implementation of the first aspect, the ionic inorganic salt includes at least one of sodium chloride, sodium sulfate, ammonium chloride, ammonium sulfate, potassium chloride, and potassium sulfate.

[0016] In this implementation, ionic inorganic salts can cause protein molecules in the formulation to adsorb a small amount of salt ions with opposite charges. The electric double layer causes protein molecules to repel each other, and the interaction between protein molecules and water molecules is strengthened, thereby increasing the solubility of protein molecules and reducing water evaporation. At the same time, ionic inorganic salts have the advantages of protecting protein molecules from denaturation. In addition, as ionic solutes, ionic inorganic salts can also play a role in regulating conductivity.

[0017] In one possible implementation of the first aspect, the albumin includes at least one of whey protein, serum protein, ovalbumin, wheat albumin, and soy albumin.

[0018] In this implementation, albumin primarily mimics proteins in the skin, which can reduce the relative permittivity and conductivity of the simulated skin tissue fluid, keeping them within the desired range.

[0019] In one possible implementation of the first aspect, the nonionic surfactant includes an oil-in-water nonionic surfactant, which includes at least one of poloxamer, fatty acid polyoxyethylene ester, polyoxyethylene alkylamine, and polyoxyethylene alkylamide.

[0020] In this implementation, the O / W type high molecular weight nonionic surfactant can form micelles to increase the surface solubility of proteins and lipids; at the same time, as an O / W type emulsifier and stabilizer, it can effectively mix water and oil and prevent water and oil separation, so that oil emulsification can be more stable; in addition, the nonionic surfactant can play a thickening role to prevent the solution from being too dilute.

[0021] In one possible implementation of the first aspect, the frequency range supported by the simulated human tissue fluid includes 10 GHz to 30 GHz.

[0022] In this implementation, APD testing can be performed in the frequency range of 10GHz to 30GHz.

[0023] In one possible implementation of the first aspect, the relative permittivity of the simulated human tissue fluid at 10 GHz ranges from 28.16 to 34.42; and / or, the relative permittivity of the simulated human tissue fluid at 12 GHz ranges from 26.40 to 32.26; and / or, the relative permittivity of the simulated human tissue fluid at 14 GHz ranges from 24.62 to 30.10; and / or, the relative permittivity of the simulated human tissue fluid at 16 GHz ranges from 22.91 to 28.01; and / or, the relative permittivity of the simulated human tissue fluid at 18 GHz ranges from 21.29 to 26.02; and / or, the relative permittivity of the simulated human tissue fluid at 20 GHz ranges from 20 GHz to 20 GHz. The relative permittivity range at GHz is 19.76 to 24.16; and / or, the relative permittivity range of simulated human tissue fluid at 22 GHz is 18.37 to 22.45; and / or, the relative permittivity range of simulated human tissue fluid at 24 GHz is 17.09 to 20.89; and / or, the relative permittivity range of simulated human tissue fluid at 26 GHz is 15.94 to 19.48; and / or, the relative permittivity range of simulated human tissue fluid at 28 GHz is 14.90 to 18.21; and / or, the relative permittivity range of simulated human tissue fluid at 30 GHz is 13.96 to 17.06.

[0024] In this implementation, the relative permittivity in the frequency range of 10 GHz to 30 GHz can be obtained.

[0025] In one possible implementation of the first aspect, the conductivity range of the simulated human tissue fluid at 10 GHz includes 7.21 S / m to 8.81 S / m; and / or, the conductivity range of the simulated human tissue fluid at 12 GHz includes 9.31 S / m to 11.37 S / m; and / or, the conductivity range of the simulated human tissue fluid at 14 GHz includes 11.42 S / m to 13.96 S / m; and / or, the conductivity range of the simulated human tissue fluid at 16 GHz includes 13.49 S / m to 16.49 S / m; and / or, the conductivity range of the simulated human tissue fluid at 18 GHz includes 15.46 S / m to 18.90 S / m; and / or, the conductivity range of the simulated human tissue fluid at 20 GHz... The conductivity range at 22 GHz includes 17.30 S / m to 21.14 S / m; and / or, the conductivity range of simulated human tissue fluid at 22 GHz includes 19.00 S / m to 23.22 S / m; and / or, the conductivity range of simulated human tissue fluid at 24 GHz includes 20.56 S / m to 25.12 S / m; and / or, the conductivity range of simulated human tissue fluid at 26 GHz includes 21.97 S / m to 26.85 S / m; and / or, the conductivity range of simulated human tissue fluid at 28 GHz includes 23.24 S / m to 28.40 S / m; and / or, the conductivity range of simulated human tissue fluid at 30 GHz includes 24.39 S / m to 29.81 S / m.

[0026] In this implementation, conductivity can be obtained in the frequency range of 10 GHz to 30 GHz.

[0027] Secondly, a method for preparing simulated human tissue fluid is provided, comprising the following steps:

[0028] After adding ionic inorganic salts to water and mixing them evenly, the first aqueous phase mixture is obtained.

[0029] After the lipids and nonionic surfactants are mixed evenly, an oil phase mixture is obtained;

[0030] The first aqueous phase mixture is added to the oil phase mixture and mixed evenly to obtain the first mixture;

[0031] Albumin and preservatives were added to the first mixture and mixed thoroughly to obtain a simulated human tissue fluid.

[0032] This application provides a method for preparing simulated human tissue fluid. By combining water, ionic inorganic salts, albumin, lipids, nonionic surfactants and preservatives, a simulated human tissue fluid capable of APD testing in the frequency range of 10GHz to 30GHz can be obtained. The method is simple to implement and has low cost.

[0033] Thirdly, a method for preparing simulated human tissue fluid is provided, comprising the following steps:

[0034] After adding ionic inorganic salts and albumin to water and mixing them evenly, a second aqueous phase mixture is obtained.

[0035] After the lipids and nonionic surfactants are mixed evenly, an oil phase mixture is obtained;

[0036] The second aqueous phase mixture is added to the oil phase mixture and mixed evenly to obtain the second mixture;

[0037] Preservatives were added to the second mixture and mixed thoroughly to obtain simulated human tissue fluid.

[0038] This application provides a method for preparing simulated human tissue fluid. By combining water, ionic inorganic salts, albumin, lipids, nonionic surfactants and preservatives, a simulated human tissue fluid capable of APD testing in the frequency range of 10GHz to 30GHz can be obtained. The method is simple to implement and has low cost.

[0039] Fourthly, a method for preparing simulated human tissue fluid is provided, comprising the following steps:

[0040] After adding ionic inorganic salts, albumin, and preservatives to water and mixing them evenly, a third aqueous phase mixture is obtained.

[0041] After the lipids and nonionic surfactants are mixed evenly, an oil phase mixture is obtained;

[0042] The third aqueous phase mixture was added to the oil phase mixture and mixed evenly to obtain a simulated human tissue fluid.

[0043] This application provides a method for preparing simulated human tissue fluid. By combining water, ionic inorganic salts, albumin, lipids, nonionic surfactants and preservatives, a simulated human tissue fluid capable of APD testing in the frequency range of 10GHz to 30GHz can be obtained. The method is simple to implement and has low cost.

[0044] This application provides a simulated human tissue fluid, its preparation method, and its application. By combining water, ionic inorganic salts, albumin, lipids, nonionic surfactants, and preservatives, a simulated human tissue fluid capable of APD testing in the frequency range of 10GHz to 30GHz is obtained. Furthermore, the simulated skin tissue fluid exhibits good stability and low cost. Attached Figure Description

[0045] Figure 1 This application provides an embodiment of a user being within the range of electromagnetic radiation generated by a mobile phone while using it;

[0046] Figure 2 This application provides an embodiment of a user being within the range of electromagnetic radiation generated by a mobile hotspot when using it;

[0047] Figure 3 This application provides an embodiment of a user being within the range of electromagnetic radiation generated by a tablet computer when using the tablet computer;

[0048] Figure 4 This application provides an embodiment of a user being within the range of electromagnetic radiation generated by a laptop computer when using it;

[0049] Figure 5 This application provides an embodiment of a situation where a user is within the range of electromagnetic radiation generated by a smartwatch when using it;

[0050] Figure 6 This provides information on the impact of a current international research frequency band on human health related to relevant technologies.

[0051] Figure 7 This is a schematic diagram illustrating the emulsification effect of simulated skin tissue fluid, provided in an embodiment of this application.

[0052] Figure 8 A flowchart illustrating the preparation process of simulated skin tissue fluid is provided in this application embodiment;

[0053] Figure 9 Another process flow diagram for preparing simulated skin tissue fluid provided in this application embodiment;

[0054] Figure 10 This is a flowchart illustrating another process for preparing simulated skin tissue fluid, provided as an embodiment of this application. Detailed Implementation

[0055] The technical solutions in the embodiments of this application will be clearly and thoroughly described below with reference to the accompanying drawings. In the description of the embodiments of this application, unless otherwise stated, " / " means "or," for example, A / B can mean A or B; the word "and / or" in the text is merely a description of the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, and B existing alone.

[0056] Hereinafter, the terms "first" and "second" are used for descriptive purposes only and should not be construed as implying relative importance or implicitly indicating the number of indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the embodiments of this application, unless otherwise stated, "multiple" means two or more. "At least one" means one or more.

[0057] First, some terms used in the embodiments of this application will be explained to enable those skilled in the art to better understand them.

[0058] 1. Absorbed power density (APD)

[0059] APD, also known as epithelial power density, is a biological dose indicator of radiation absorption in the human body. It refers to the electromagnetic energy absorbed per unit time and per unit volume and is commonly used to measure the impact of electromagnetic radiation on human health.

[0060] 2. Whey protein

[0061] Whey protein refers to proteins dissolved and dispersed in whey. Whey protein accounts for approximately 25% of the skin.

[0062] 3. Serum protein

[0063] Serum proteins are carriers of fatty acids in the blood. When the body needs energy or building materials, fat cells release fatty acids into the blood. These fatty acids are then captured by serum proteins and transported to the areas where they are needed.

[0064] 4. Ovalbumin

[0065] Ovalbumin is a typical globulin with a molecular weight of 44.5 kDa. It is a phosphoglycoprotein containing four free sulfhydryl groups and 385 amino acid residues. These amino acid residues intertwine and fold together to form a globular structure with a high degree of secondary structure, mostly consisting of α-helices and β-sheets.

[0066] 5. Wheat whey protein

[0067] Wheat protein is an enzyme protein in the cytoplasm, including α-amylase, protease inhibitors, regulatory enzymes, synthetic enzymes and metabolic enzymes of specific pathways.

[0068] 6. Soy whey protein

[0069] Soy protein is a protein that exhibits thermal coagulation properties.

[0070] 7. Triglycerides, saturated triglycerides, and unsaturated triglycerides

[0071] Fat, also known as triglycerides, is a compound composed of one glycerol molecule and three fatty acid molecules. The content of triglycerides in the skin is about 3%.

[0072] Triglycerides are classified as "saturated" and "unsaturated," primarily based on the structure of fatty acids. Saturated fatty acids lack unsaturated double bonds in their carbon chains, and oils rich in saturated fatty acids are solid at room temperature. Unsaturated fatty acids contain one or more unsaturated double bonds, and oils rich in unsaturated fatty acids are liquid at room temperature.

[0073] 8. Phosphatidyl ethanolamine (PE)

[0074] PE is a phospholipid composed of glycerol, fatty acids, phosphoric acid, and ethanolamine. It is found in the brain, nerves, and soybeans, and is an excellent natural surfactant with unique biological activity and physiological functions. It is non-toxic, non-irritating, and does not pollute the environment.

[0075] 9. Phosphatidyl inositol (PI)

[0076] PI is mainly composed of two parts: 1,2-diacoyl glycerol phosphate and inositol. It plays a very important role in cell morphology, metabolic regulation, signal transduction and various physiological functions of cells.

[0077] 10. Phosphatidyl serine (PS)

[0078] PS, also known as complex nervonic acid, is an active substance in cell membranes, especially in brain cells. It mainly plays a role in improving nerve cell function, regulating nerve impulse transmission, and enhancing brain memory. Due to its strong lipophilicity, it can quickly cross the blood-brain barrier and enter the brain after absorption. It can also relax vascular smooth muscle cells and increase blood supply to the brain.

[0079] 11. Phosphatidylglycerol (PG)

[0080] PG is a glycerophospholipid containing a triglyceride core structure. Its molecule contains a phosphate group, a fatty acid chain, and a hydrophilic head group, which can be ethanolamine, choline, or serine. Due to its structural characteristics, PG plays a key role in the formation and maintenance of cell membranes and participates in a variety of biological processes.

[0081] 12. Phosphatidylcholine (PC)

[0082] PC is a type of phospholipid and an amphipathic molecule, consisting of a hydrophilic head and a hydrophobic tail. A choline group is inserted into the head. It is an important component of brown fat in biological membranes, animal and plant tissues.

[0083] 13. Nonionic surfactants

[0084] Nonionic surfactants do not have charged groups in their molecules and do not ionize in aqueous solutions. Their lipophilic groups include higher fatty alcohols, alkylphenols, fatty acids, fatty amines, and oils. Their water solubility comes from polyoxyethylene ether groups and terminal hydroxyl groups in the molecule.

[0085] 14. Poloxamer

[0086] Poloxamer is a high molecular weight nonionic surfactant, which is a block copolymer of polyoxyethylene and polyoxypropylene ether.

[0087] 15. Polyoxyethylene fatty acid

[0088] Fatty acid polyoxyethylene ester is also known as emulsifier A, with the molecular formula RCOO(CH2CH2O). n H.

[0089] 16. Polyoxyethylene alkanolamide

[0090] Polyoxyethylene alkanolamide is a nonionic surfactant synthesized from alkanolamide and ethylene oxide.

[0091] 17. Water-in-oil

[0092] Oil-in-water emulsions, denoted as O / W, refer to emulsion systems in which oil is dispersed in water, with oil as the internal phase and water as the continuous external phase. If the surfactant has strong hydrophilicity, its solubility in water is greater than in oil, making it easier to form an O / W emulsion.

[0093] The above is a brief introduction to the terms used in the embodiments of this application, and will not be repeated below.

[0094] To facilitate understanding of the embodiments of this application, the application background of this application will be introduced below.

[0095] With the development of wireless communication technology, people are exposed to electromagnetic radiation more and more frequently. Since organs and tissues in the human body are lossy media, the electromagnetic field within the body generates current, thereby absorbing and dissipating electromagnetic energy. Therefore, while enjoying the various conveniences brought by wireless communication, people are increasingly concerned about the impact of electromagnetic radiation generated by wireless communication on human health.

[0096] Electronic devices that typically generate electromagnetic radiation include mobile phones, wearable devices such as smart bracelets, headphones, and smartwatches, tablets, laptops, handheld computers, laptops, ultra-mobile personal computers (UMPCs), cellular phones, personal digital assistants (PDAs), Internet of Things (IoT) devices such as augmented reality (AR) and virtual reality (VR) devices, in-vehicle electronic devices, and televisions.

[0097] In addition, Wi-Fi also generates electromagnetic radiation when people use mobile hotspots (wireless fidelity, Wi-Fi) on electronic devices.

[0098] For example, Figure 1 This diagram illustrates the electromagnetic radiation emitted when a user uses a mobile phone. Figure 2 This diagram illustrates the electromagnetic radiation emitted when a user uses Wi-Fi. Figure 3 A schematic diagram of electromagnetic radiation when a user uses a tablet computer is shown. Figure 4 This diagram illustrates electromagnetic radiation emitted when a user is using a laptop computer. Figure 5 A schematic diagram of electromagnetic radiation when a user uses a smartwatch is shown.

[0099] exist Figures 1 to 5 In the diagrams, the dotted lines represent the range of electromagnetic radiation emitted by mobile phones, Wi-Fi, tablets, laptops, and smartwatches at different parts and tissues of the human body. Figures 1 to 5 As shown, the parts and tissues in the human body that absorb electromagnetic radiation from mobile phones, Wi-Fi, tablets, laptops, and smartwatches are not entirely the same.

[0100] Given that users are exposed to electromagnetic fields, different parts and tissues of the human body will absorb a certain dose of radiation. In order to ensure people's safety, countries and regions around the world have been gradually tightening regulations on radio frequency absorption in the human body. To date, many countries and regions have made regulations on human safety. Meanwhile, international regional telecommunications organizations have made more refined allocations of electromagnetic radiation frequency bands, especially those involving commercial electromagnetic radiation. For example, the Arab Spectrum Management Group (ASMG) has allocated the 3.8GHz–4.2GHz and 7GHz–15GHz electromagnetic radiation frequency bands for commercial use; the Regional Commonwealth in the Field of Communications (RCC) has allocated the 4.4GHz–4.8GHz, 10GHz–10.5GHz, and 14.8GHz–15.35GHz electromagnetic radiation frequency bands for commercial use; and the Inter-American Telecommunication Commission (CITEL) has allocated the 3.1GHz–3.3GHz, 7.125GHz–8.5GHz, and 14.75GHz–15.35GHz electromagnetic radiation frequency bands for commercial use. It is evident that the International Telecommunication Union has allocated the 10GHz-30GHz frequency band for commercial use. It is foreseeable that the 10GHz-30GHz frequency band will be used in electronic devices in the near future. Therefore, it is necessary to conduct radiation assessment and testing on the 10GHz-30GHz frequency band.

[0101] In related technologies, the effects of electromagnetic radiation at specific frequencies are assessed by testing a liquid simulating the human body within a fluid sample matched to a particular frequency band. Specifically, the absorbable radiation dose (APD) of the simulated human body can be characterized by performing an APD test on the fluid.

[0102] However, the formulations of most human body simulation fluids currently used are kept confidential. Therefore, to conduct APD testing, it's necessary to purchase human body simulation fluids for the required test frequency band, but these fluids are typically very expensive. For example, the human body simulation fluids used in SAR certification laboratories for frequencies below 10GHz are sourced from the Swiss company SPEAG, with an average annual purchase cost of approximately 200,000 RMB, resulting in very high costs. Furthermore, the dielectric constant and conductivity of most human body simulation fluids change after frequent use over a period of time, affecting the accuracy of APD testing. These abnormalities cannot be corrected promptly. Additionally, human body simulation fluids have strict storage requirements and a short shelf life, resulting in poor long-term stability; some have a shelf life of less than two years. Therefore, to conduct APD testing, new human body simulation fluids need to be purchased, further increasing costs. More importantly, there are currently no human body simulation fluids available in the industry for the 10GHz–30GHz frequency band, making APD testing impossible in this band.

[0103] In view of this, this application provides a simulated human body liquid corresponding to the 10GHz to 30GHz frequency band, which can be used for APD testing in the 10GHz to 30GHz frequency band.

[0104] Figure 6 This demonstrates the health effects of frequency bands currently studied internationally.

[0105] like Figure 6 As shown, current international research indicates that:

[0106] I. Radiation absorption in the 0MHz to 10MHz frequency range mainly affects the human nervous system, which may cause nerve stimulation and lead to nerve tingling and other symptoms.

[0107] II. Radiation absorption in the 10MHz to 10GHz frequency range mainly affects human organs and tissues, possibly due to thermal effects causing temperature increases.

[0108] Third, radiation absorption in the 10GHz to 300GHz frequency range mainly affects some tissues and skin of the human body, and may cause temperature rise due to tissue heating.

[0109] Table 1 shows the effects of some frequencies in the 6GHz–300GHz band on the human body, based on current international research.

[0110] Table 1

[0111] Frequency (GHz) Penetration depth of dry skin (mm) 6 4.09 10 1.9 30 0.43 94 0.19 100 0.18 300 0.14

[0112] Based on Table 1 Figure 6 It is known that as the frequency of electromagnetic radiation increases, the depth of its impact on the human body becomes shallower. For example, the 10GHz to 30GHz frequency band mainly affects the surface of the human skin, rather than other organs.

[0113] Based on the above, this application provides a simulated human body liquid and its preparation method. Since the 10GHz to 30GHz frequency band mainly affects the surface of human skin, the simulated human body liquid provided in this application is a simulated skin tissue fluid, which can be used to achieve APD testing in the 10GHz to 30GHz frequency band.

[0114] This application provides a simulated skin tissue fluid, which comprises, by mass percentage:

[0115] Water, 55wt%–75wt%.

[0116] Ionic inorganic salts, 2wt%–5wt%.

[0117] Albumin, 10wt%–18wt%.

[0118] Lipids, 12 wt% to 20 wt%.

[0119] Nonionic surfactant, 2wt%–4wt%.

[0120] Preservative, 0.2wt% to 1wt%.

[0121] In practical applications, since the human body is about 60% water, water is used as the solvent to simulate skin tissue fluid.

[0122] Furthermore, deionized water (DIO) can be used as a solvent. Deionized water has fewer ionic impurities and a neutral pH value, which can minimize the occurrence of impurities or pH affecting the solubility of solutes during solution preparation.

[0123] It should be noted that after the simulated skin tissue fluid is prepared, the dielectric constant will decrease and the conductivity will increase as the solvent evaporates. Therefore, a certain amount of solvent can be added at different stages as needed to increase the dielectric constant and decrease the conductivity, so that the dielectric constant and conductivity of the simulated skin tissue fluid are maintained within the required range.

[0124] For example, water may be 55 wt%, 60 wt%, 65 wt%, 68 wt%, 70 wt%, or 75 wt% by mass percentage, etc.

[0125] In practical applications, ionic inorganic salts mainly mimic the inorganic salts found in the skin. The specific types of ionic inorganic salts are not limited; for example, they may include sodium chloride (NaCl), sodium sulfate (Na₂SO₄), ammonium chloride (NH₄Cl), ammonium sulfate ((NH₄)₂SO₄), potassium chloride (KCl), and potassium sulfate (K₂SO₄), etc.

[0126] Furthermore, the aforementioned ionic inorganic salt can be an ionic inorganic salt with a certain concentration, and the concentration range of the ionic inorganic salt can be 2% to 7%. For example, the concentration of the ionic inorganic salt can be 2%, 3%, 4%, 5%, 6%, or 7%, etc.

[0127] By adding a certain concentration of ionic inorganic salts, protein molecules in the formula can adsorb a small amount of salt ions with opposite charges. The electric double layer causes the protein molecules to repel each other, and the interaction between protein molecules and water molecules is strengthened, thereby increasing the solubility of protein molecules and reducing water evaporation. At the same time, a certain concentration of ionic inorganic salts is a dilute salt solution. Dilute salt solutions have the advantage of protecting protein molecules from denaturation because the salt ions partially bind to the protein molecules. In addition, as ionic solutes, ionic inorganic salts can also play a role in regulating conductivity.

[0128] For example, ionic inorganic salts can be 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, or 5 wt% by mass percentage.

[0129] In practical applications, albumin mainly mimics proteins in the skin. These proteins can reduce the dielectric constant and conductivity of the simulated skin tissue fluid, keeping them within the required range.

[0130] There is no specific limitation on the type of albumin. For example, albumin may include whey protein, serum protein, ovalbumin, wheat albumin, and soy albumin.

[0131] Furthermore, since whey protein is a highly water-soluble protein, it is preferred as the whey protein for use. Specifically, whey protein with CAS number 84082-51-9 can be selected.

[0132] For example, albumin may be 10 wt%, 11 wt%, 13 wt%, 14 wt%, 15 wt%, or 18 wt% by weight.

[0133] In practical applications, lipids mainly mimic the fat in the skin. Lipids can reduce the dielectric constant and conductivity of the simulated skin tissue fluid, keeping them within the required range.

[0134] The specific types of lipids mentioned above are not limited. For example, lipids may include one or more combinations of oils, sterols, and phospholipids. It should be noted that if phospholipids are not added to the formulation, the amount of nonionic surfactant needs to be appropriately increased to achieve a better emulsification effect.

[0135] Fats and oils may include triglycerides (chemical formula: )wait.

[0136] Furthermore, triglycerides can include unsaturated triglycerides (liquid at room temperature) and saturated triglycerides (solid at room temperature).

[0137] Sterols can include cholesterol, among other things.

[0138] Phospholipids may include phosphatidylcholine (chemical formula: Phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidylglycerol, etc.

[0139] Furthermore, since saturated triglycerides are solid at room temperature, if saturated triglycerides are added and in high amounts, the simulated skin tissue fluid will coagulate, making it impossible to synthesize the desired liquid simulated skin tissue fluid. Therefore, in this embodiment, the lipids are set to include at least unsaturated triglycerides, and the percentage content of unsaturated triglycerides in the lipids is greater than or equal to 90%. For example, the percentage content of unsaturated triglycerides in the lipids can be 90%, 91%, 93%, 94%, 95%, or 100%, etc. Thus, by adding a large amount of unsaturated triglycerides that are liquid at room temperature, the desired liquid simulated skin tissue fluid can be synthesized.

[0140] Among them, unsaturated triglycerides can be derived from vegetable oils such as rapeseed oil, soybean oil, and peanut oil, or from specially purchased chemicals, etc., without specific limitations.

[0141] It should be noted that the triglycerides mentioned above are nonpolar lipids.

[0142] Furthermore, the percentage content of phospholipids in lipids can range from 0% to 4%. For example, the percentage content of phospholipids in lipids can be 0%, 1%, 2%, 3%, 3.5%, or 4%, etc., so that a certain amount of phospholipids can achieve a good emulsifying effect. It should be noted that when the percentage content of phospholipids in lipids is 0%, it means that no phospholipids have been added.

[0143] Furthermore, the percentage content of sterols in lipids can range from 0% to 2%. For example, the percentage content of sterols in lipids can be 0%, 0.5%, 1%, 1.5%, or 2%, etc., thereby better mimicking human skin. It should be noted that when the percentage content of sterols in lipids is 0%, it means that no sterols have been added.

[0144] It should be noted that the phosphatidylcholine mentioned above is a polar lipid that can mimic the polar lipids in the skin; at the same time, phosphatidylcholine is both hydrophilic and lipophilic, and is an O / W type surfactant that can be used as an emulsifier to fully mix water and oil.

[0145] For example, the lipids may be 12 wt%, 13 wt%, 14 wt%, 16 wt%, 18 wt%, or 20 wt% by mass percentage, etc.

[0146] In practical applications, there is no limitation on the specific types of nonionic surfactants. For example, nonionic surfactants can include O / W type nonionic surfactants, such as poloxamer, fatty acid polyoxyethylene esters, polyoxyethylene alkylamines, and polyoxyethylene alkylamides.

[0147] Among them, the chemical formula of poloxamer is Poloxamer is a high-molecular-weight nonionic surfactant that can form micelles to increase the surface solubility of proteins and lipids. At the same time, as an O / W type emulsifier and stabilizer, it can effectively mix water and oil, preventing water and oil separation, thus making oil emulsification more stable. In addition, poloxamer can act as a thickener to prevent the solution from becoming too dilute.

[0148] Figure 7 The emulsifying effect of nonionic surfactants is shown.

[0149] like Figure 7 As shown, the middle phase is the oil phase, which includes the lipids in the formulation; the outermost ring is the aqueous phase, which includes the water in the formulation. The oil phase and the aqueous phase are connected by a nonionic surfactant.

[0150] For example, the nonionic surfactant may be 2 wt%, 2.6 wt%, 3 wt%, 3.5 wt%, 3.8 wt%, or 4 wt% by mass percentage.

[0151] In practical applications, the specific types of preservatives mentioned above are not limited. For example, preservatives may include water-soluble preservatives. Water-soluble preservatives can prevent the active ingredients from becoming moldy and deteriorating, or they can prevent the active ingredients from being decomposed by microorganisms, effectively extending the usability of simulated skin tissue fluid.

[0152] For example, the preservative may be 0.2wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.8wt%, or 1wt% by weight.

[0153] The relative permittivity of the simulated human tissue fluid obtained above ranges from 28.16 to 34.42 at 10 GHz; from 26.40 to 32.26 at 12 GHz; from 24.62 to 30.10 at 14 GHz; from 22.91 to 28.01 at 16 GHz; from 21.29 to 26.02 at 18 GHz; and from 20 GHz. The relative permittivity ranges from 19.76 to 24.16; the relative permittivity of simulated human tissue fluid at 22 GHz ranges from 18.37 to 22.45; the relative permittivity of simulated human tissue fluid at 24 GHz ranges from 17.09 to 20.89; the relative permittivity of simulated human tissue fluid at 26 GHz ranges from 15.94 to 19.48; the relative permittivity of simulated human tissue fluid at 28 GHz ranges from 14.90 to 18.21; and the relative permittivity of simulated human tissue fluid at 30 GHz ranges from 13.96 to 17.06.

[0154] The conductivity of the simulated human tissue fluid obtained above ranges from 7.21 S / m to 8.81 S / m at 10 GHz; from 9.31 S / m to 11.37 S / m at 12 GHz; from 11.42 S / m to 13.96 S / m at 14 GHz; from 13.49 S / m to 16.49 S / m at 16 GHz; from 15.46 S / m to 18.90 S / m at 18 GHz; and from 20 GHz. The conductivity ranges from 17.30 S / m to 21.14 S / m; the conductivity range of simulated human tissue fluid at 22 GHz is 19.00 S / m to 23.22 S / m; the conductivity range of simulated human tissue fluid at 24 GHz is 20.56 S / m to 25.12 S / m; the conductivity range of simulated human tissue fluid at 26 GHz is 21.97 S / m to 26.85 S / m; the conductivity range of simulated human tissue fluid at 28 GHz is 23.24 S / m to 28.40 S / m; and the conductivity range of simulated human tissue fluid at 30 GHz is 24.39 S / m to 29.81 S / m.

[0155] This application provides a simulated skin tissue fluid, which accurately simulates human skin through the combination of water, ionic inorganic salts, albumin, lipids, nonionic surfactants and preservatives. Specifically, it simulates the electrical conductivity and electrical parameters of human skin, thereby enabling APD testing in the frequency range of 10GHz to 30GHz. This simulated skin tissue fluid has good stability and low cost, which is conducive to its widespread use.

[0156] Optionally, as one possible implementation, the simulated skin tissue fluid provided in this application embodiment comprises, by mass percentage:

[0157] Deionized water, 55wt%–75wt%.

[0158] Sodium sulfate, 2 wt% to 5 wt%.

[0159] Whey protein, 10wt%–18wt%.

[0160] Triglycerides, 8 wt% to 15 wt%; wherein, the percentage content of unsaturated triglycerides in triglycerides is greater than or equal to 90%.

[0161] Phosphatidylcholine, 2wt%–4wt%.

[0162] Poloxamer, 2 wt% to 4 wt%.

[0163] Water-based preservative, 0.2wt% to 1wt%.

[0164] For example, deionized water can be 55wt%, 60wt%, 65wt%, 68wt%, 70wt%, or 75wt% by mass percentage.

[0165] Sodium sulfate can be present in the form of 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, or 5 wt% by mass percentage.

[0166] Whey protein can be expressed as a percentage by weight, such as 10wt%, 11wt%, 13wt%, 14wt%, 15wt%, or 18wt%.

[0167] The triglycerides can be 8 wt%, 9 wt%, 10 wt%, 12 wt%, 14 wt%, or 15 wt% by mass percentage; among them, the percentage content of unsaturated triglycerides in the triglycerides can be 90%, 91%, 92%, 93%, 94%, or 95%.

[0168] Phosphatidylcholine can be present in the form of 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 3.8 wt%, or 4 wt% by mass percentage.

[0169] Poloxamer can be present in the form of 2 wt%, 2.6 wt%, 3 wt%, 3.5 wt%, 3.8 wt%, or 4 wt% by weight.

[0170] Water-based preservatives can be present in percentages of mass such as 0.2wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.8wt%, or 1wt%.

[0171] This application provides a simulated skin tissue fluid that can simulate the surface skin of the human body, and can be used for APD testing in the range of 10 GHz to 30 GHz. At the same time, the simulated skin tissue fluid has relatively low cost and good stability.

[0172] Figures 8 to 10 Various different methods for preparing simulated skin tissue fluid provided in the embodiments of this application are illustrated.

[0173] Figure 8 The first method for preparing simulated skin tissue fluid is shown.

[0174] like Figure 8 As shown, the method for preparing simulated skin tissue fluid includes the following steps:

[0175] S11. After adding ionic inorganic salts to water and mixing them evenly, a first aqueous phase mixture is obtained.

[0176] It should be noted that the above process involves dissolving ionic inorganic salts in water, and no chemical reaction occurs.

[0177] S12. After uniformly mixing the lipids and nonionic surfactants, an oil phase mixture is obtained.

[0178] It should be noted that the above process involves mixing oil and water to obtain a suspension, and no chemical reaction occurs.

[0179] S13. Add the first aqueous phase mixture to the oil phase mixture, mix thoroughly to obtain the first mixture.

[0180] It should be noted that the aqueous phase must be added to the oil phase to create the desired oil-in-water (O / W) liquid; an oil-in-water (W / O) liquid will not mix evenly. Furthermore, because the testing equipment moves throughout the simulated skin tissue fluid, the electrical parameters of each part of the simulated skin tissue fluid must be identical. Only when the oil-in-water (O / W) liquid is in a homogeneous state can the corresponding tests be performed effectively.

[0181] S14. Add albumin and preservative to the first mixture, mix well, and obtain simulated human tissue fluid.

[0182] The following is a specific method for preparing simulated skin tissue fluid, using the following as an example: Deionized water, 55wt%–75wt%; Sodium sulfate, 2wt%–5wt%; Whey protein, 10wt%–18wt%; Triglycerides, 8wt%–15wt%, wherein unsaturated triglycerides comprise ≥90% of the total triglycerides; Phosphatidylcholine, 2wt%–4wt%; Poloxamer, 2wt%–4wt%; and Aqueous preservative, 0.2wt%–1wt%.

[0183] It should be noted that the temperature range for all operations in this application embodiment is 19°C to 25°C.

[0184] The specific preparation method includes the following steps:

[0185] (1). Preparation of aqueous phase: Sodium sulfate was added to deionized water and stirred until fully dissolved to obtain aqueous phase.

[0186] (2). Preparation of oil phase: Triglycerides, phosphatidylcholine and poloxamer are thoroughly mixed and stirred for more than 10 minutes to obtain the oil phase.

[0187] (3) Add the prepared aqueous phase to the oil phase and stir thoroughly again until the water and oil are mixed to obtain the tissue fluid.

[0188] (4) Add whey protein and water-based preservative to the tissue fluid and stir again for more than 5 minutes to obtain simulated human tissue fluid.

[0189] Figure 9 A second method for preparing simulated skin tissue fluid is shown.

[0190] like Figure 9 As shown, the method for preparing simulated skin tissue fluid includes the following steps:

[0191] S21. After adding ionic inorganic salts and albumin to water and mixing them evenly, a second aqueous phase mixture is obtained.

[0192] S22. After uniformly mixing lipids and nonionic surfactants, an oil phase mixture is obtained.

[0193] S23. Add the second aqueous phase mixture to the oil phase mixture, mix thoroughly, and obtain the second mixture.

[0194] S24. Add the preservative to the second mixture, mix well, and obtain simulated human tissue fluid.

[0195] The following is a specific method for preparing simulated skin tissue fluid, using the following as an example: Deionized water, 55wt%–75wt%; Sodium sulfate, 2wt%–5wt%; Whey protein, 10wt%–18wt%; Triglycerides, 8wt%–15wt%, wherein unsaturated triglycerides comprise ≥90% of the total triglycerides; Phosphatidylcholine, 2wt%–4wt%; Poloxamer, 2wt%–4wt%; and Aqueous preservative, 0.2wt%–1wt%.

[0196] It should be noted that the temperature range for all operations in this application embodiment is 19°C to 25°C.

[0197] The specific preparation method includes the following steps:

[0198] (1). Preparation of aqueous phase: Sodium sulfate and whey protein were added to deionized water and stirred until fully dissolved to obtain aqueous phase.

[0199] (2). Preparation of oil phase: Triglycerides, phosphatidylcholine and poloxamer were thoroughly mixed and stirred to obtain the oil phase.

[0200] (3) Add the prepared aqueous phase to the oil phase and stir thoroughly again until the water and oil are mixed to obtain the tissue fluid.

[0201] (4) Add the water-soluble preservative to the tissue fluid and stir to dissolve it to obtain simulated human tissue fluid.

[0202] Figure 10 A third method for preparing simulated skin tissue fluid is shown.

[0203] like Figure 10 As shown, the method for preparing simulated skin tissue fluid includes the following steps:

[0204] S31. After adding ionic inorganic salts, albumin and preservatives to water and mixing them evenly, a third aqueous phase mixture is obtained.

[0205] S32. After uniformly mixing lipids and nonionic surfactants, an oil phase mixture is obtained.

[0206] S33. Add the third aqueous phase mixture to the oil phase mixture, mix thoroughly, and obtain simulated human tissue fluid.

[0207] The following is a specific method for preparing simulated skin tissue fluid, using the following as an example: Deionized water, 55wt%–75wt%; Sodium sulfate, 2wt%–5wt%; Whey protein, 10wt%–18wt%; Triglycerides, 8wt%–15wt%, wherein unsaturated triglycerides comprise ≥90% of the total triglycerides; Phosphatidylcholine, 2wt%–4wt%; Poloxamer, 2wt%–4wt%; and Aqueous preservative, 0.2wt%–1wt%.

[0208] It should be noted that the temperature range for all operations in this application embodiment is 19°C to 25°C.

[0209] The specific preparation method includes the following steps:

[0210] (1). Preparation of aqueous phase: Sodium sulfate, whey protein and water-soluble preservative are added to deionized water and stirred until fully dissolved to obtain aqueous phase.

[0211] (2). Preparation of oil phase: Triglycerides, phosphatidylcholine and poloxamer were thoroughly mixed and stirred to obtain the oil phase.

[0212] (3) Add the prepared aqueous phase to the oil phase and stir thoroughly again until the water and oil are mixed to obtain simulated human tissue fluid.

[0213] The following examples illustrate the preparation method and application of simulated skin tissue fluid according to the embodiments of this application.

[0214] Example 1

[0215] I. Formula for simulating skin tissue fluid:

[0216] The simulated skin tissue fluid, by mass percentage, comprises: deionized water, 65 wt%; ammonium sulfate, 4 wt%; whey protein, 15 wt%; triglycerides, 10 wt%, of which unsaturated triglycerides account for 91% of the total triglycerides; phosphatidylcholine, 3 wt%; poloxamer, 2.6 wt%; and aqueous preservative, 0.4 wt%.

[0217] II. Preparation method of simulated skin tissue fluid:

[0218] (1). Preparation of aqueous phase: Sodium sulfate is added to deionized water and stirred until fully dissolved.

[0219] (2). Oil phase preparation: Triglycerides, phosphatidylcholine and poloxamer are thoroughly mixed and stirred for more than 10 minutes.

[0220] (3) Add the prepared aqueous phase to the oil phase and stir thoroughly again until the water and oil are mixed.

[0221] (4) Add whey protein and water-based preservative to the final tissue fluid and stir again for more than 5 minutes to obtain simulated skin tissue fluid.

[0222] It should be noted that the simulated skin tissue fluid prepared by the above formula has excellent long-term stability, and the electrical parameters at each frequency also meet the requirements of the APD test.

[0223] Example 2

[0224] I. Formula for simulating skin tissue fluid:

[0225] The simulated skin tissue fluid, by mass percentage, comprises: deionized water, 70 wt%; ammonium sulfate, 3 wt%; soy protein, 13 wt%; triglycerides, 8 wt%, of which unsaturated triglycerides account for 95% of the total triglycerides; cholesterol, 2 wt%; poloxamer, 3 wt%; and aqueous preservative, 1 wt%.

[0226] II. Preparation method of simulated skin tissue fluid:

[0227] (1). Aqueous phase preparation: Sodium sulfate and soy protein were added to deionized water and stirred until fully dissolved.

[0228] (2). Oil phase preparation: Triglycerides, cholesterol and poloxamer are thoroughly mixed and stirred.

[0229] (3) Add the prepared aqueous phase to the oil phase and stir thoroughly again until the water and oil are mixed.

[0230] (4) Add the water-soluble preservative to the final tissue fluid and stir to dissolve.

[0231] Example 3:

[0232] I. Formula for simulating skin tissue fluid:

[0233] The simulated skin tissue fluid, by weight percentage, comprises: deionized water, 60 wt%; sodium sulfate, 5 wt%; ovalbumin, 18 wt%; triglycerides, 9 wt%, of which unsaturated triglycerides account for 90%; cholesterol, 2 wt%; phosphatidylcholine, 2 wt%; fatty acid polyoxyethylene ester, 3 wt%; and aqueous preservative, 1 wt%.

[0234] II. Preparation method of simulated skin tissue fluid:

[0235] (1). Aqueous phase preparation: Sodium sulfate, ovalbumin and water-soluble preservative were added to the deionized water and stirred until fully dissolved.

[0236] (2). Oil phase preparation: Triglycerides, cholesterol, phosphatidylcholine and poloxamer are thoroughly mixed and stirred.

[0237] (3) Add the prepared aqueous phase to the oil phase and stir thoroughly again until the water and oil are mixed.

[0238] The relative permittivity and conductivity of the simulated skin tissue fluids prepared in Examples 1 to 3 of this application are tested below. The results obtained in Example 1 are shown in Table 2 below, the results obtained in Example 2 are shown in Table 3 below, and the results obtained in Example 3 are shown in Table 4 below.

[0239] Furthermore, Tables 2-4 provide the relative permittivity and conductivity of the simulated human body fluids provided in the reference examples, and calculate the percentage differences between the relative permittivity and conductivity of Examples 1-3 and the reference examples, which are recorded in Tables 2-4 respectively. It should be noted that the reference examples are based on relative permittivity and conductivity measured at 10 GHz to 30 GHz from research papers and literature.

[0240] Table 2

[0241]

[0242] As can be seen from Table 2, the relative permittivity and conductivity measured in Example 1 are all within -10% to 10% of the relative permittivity and conductivity of the reference example, indicating that the simulated skin tissue fluid provided in Example 1 of this application can be used and applied to 10GHz to 30GHz.

[0243] Table 3

[0244]

[0245] As can be seen from Table 3, the relative permittivity and conductivity measured in Example 2 are all within -10% to 10% of the relative permittivity and conductivity of the reference example, indicating that the simulated skin tissue fluid provided in Example 2 of this application can be used and applied to 10GHz to 30GHz.

[0246] Table 4

[0247]

[0248] As can be seen from Table 4, the relative permittivity and conductivity measured in Example 3 are all within -10% to 10% of the relative permittivity and conductivity of the reference example, indicating that the simulated skin tissue fluid provided in Example 3 of this application can be used and applied to 10GHz to 30GHz.

[0249] It should be noted that the instruments used to test the relative permittivity and conductivity in Examples 1 to 3 of this application are various models of coaxial electrical parameter probes and various series of network analyzers.

[0250] The test steps for the relative permittivity and conductivity of Examples 1 to 3 of this application are as follows:

[0251] 1. Connect the coaxial probe to the network analyzer.

[0252] 2. Use the open circuit, short circuit, and load methods to calibrate the probe.

[0253] 3. Take a portion of the simulated skin tissue fluid into a beaker and measure its temperature.

[0254] 4. Place the probe into simulated skin tissue fluid and scrape off any blisters.

[0255] 5. Set the frequency range, input the temperature of the simulated skin tissue fluid, and start the measurement.

[0256] 6. Read the relative permittivity and conductivity of simulated skin tissue fluid at each frequency.

[0257] The simulated skin tissue fluid prepared in Examples 1 to 3 of this application and the simulated human body fluid provided in the reference example were placed for 16 days. The relative permittivity of Examples 1 to 3 and the reference example was tested every other day. The measured relative permittivity was normalized, and the results are shown in Table 5 below.

[0258] Table 5

[0259]

[0260] As shown in Table 5, the relative permittivity of the simulated skin tissue fluid prepared in Examples 1 to 3 of this application, and the simulated human body fluid provided in the reference example, gradually decreases due to water evaporation, and the decrease becomes more pronounced with longer storage time. Therefore, water needs to be added to the simulated skin tissue fluid prepared in Examples 1 to 3 of this application to restore its relative permittivity, thus the product has better stability.

[0261] The above only introduces the content related to the inventive point. Other content can be obtained by referring to relevant technologies, and will not be explained in detail here.

[0262] It should be understood that the above description is merely to help those skilled in the art better understand the embodiments of this application, and is not intended to limit the scope of the embodiments of this application. Those skilled in the art can obviously make various equivalent modifications or variations based on the examples given above, or combinations of any two or more of the above embodiments. Such modifications, variations, or combinations also fall within the scope of the embodiments of this application.

[0263] It should also be understood that the above description of the embodiments of this application focuses on highlighting the differences between the various embodiments. Any similarities or differences not mentioned can be referred to each other. For the sake of brevity, they will not be repeated here.

[0264] It should also be understood that the methods, situations, categories, and classifications of embodiments in this application are for the convenience of description only and should not constitute a special limitation. Various methods, categories, situations, and features in embodiments can be combined without contradiction.

[0265] It should also be understood that, in the various embodiments of this application, unless otherwise specified or in case of logical conflict, the terms and / or descriptions between different embodiments are consistent and can be referenced by each other, and the technical features in different embodiments can be combined to form new embodiments according to their inherent logical relationships.

[0266] Finally, it should be noted that the above descriptions are merely specific embodiments of this application, but the scope of protection of this application is not limited thereto. Any variations or substitutions within the technical scope disclosed in this application should be included within the scope of protection of this application. Therefore, the scope of protection of this application should be determined by the scope of the claims.

Claims

1. A simulated human tissue fluid, characterized in that, The simulated human tissue fluid is used to support absorbed power density testing in a frequency range of 10 GHz to 30 GHz, and the simulated human tissue fluid comprises, by mass percentage: Water, 55wt%~75wt%; Ionic inorganic salts, 2wt%~5wt%; Albumin, 10wt%~18wt%; Lipids, 12wt%~20wt%; Nonionic surfactant, 2wt%~4wt%; Preservatives, 0.2wt%~1wt%.

2. The simulated human tissue fluid according to claim 1, characterized in that, The lipids comprise at least unsaturated triglycerides, and the percentage of unsaturated triglycerides in the lipids is greater than or equal to 90%.

3. The simulated human tissue fluid according to claim 2, characterized in that, When the percentage content of the unsaturated triglyceride in the lipid is less than 100%, the lipid further includes at least one of oils, sterols and phospholipids.

4. The simulated human tissue fluid according to any one of claims 1 to 3, characterized in that, The water includes deionized water.

5. The simulated human tissue fluid according to any one of claims 1 to 4, characterized in that, The ionic inorganic salts include at least one of sodium chloride, sodium sulfate, ammonium chloride, ammonium sulfate, potassium chloride, and potassium sulfate.

6. The simulated human tissue fluid according to any one of claims 1 to 5, characterized in that, The albumin includes at least one of whey protein, serum protein, ovalbumin, wheat albumin, and soy albumin.

7. The simulated human tissue fluid according to any one of claims 1 to 6, characterized in that, The nonionic surfactant includes an oil-in-water type, which includes at least one of poloxamer, fatty acid polyoxyethylene ester, polyoxyethylene alkylamine, and polyoxyethylene alkylamide.

8. The simulated human tissue fluid according to any one of claims 1 to 7, characterized in that, The relative permittivity of the simulated human tissue fluid at 10 GHz ranges from 28.16 to 34.

42. And / or, The relative permittivity of the simulated human tissue fluid at 12 GHz ranges from 26.40 to 32.

26. And / or, The relative permittivity of the simulated human tissue fluid at 14 GHz ranges from 24.62 to 30.

10. And / or, The relative permittivity of the simulated human tissue fluid at 16 GHz ranges from 22.91 to 28.

01. And / or, The relative permittivity of the simulated human tissue fluid at 18 GHz ranges from 21.29 to 26.

02. And / or, The relative permittivity of the simulated human tissue fluid at 20 GHz ranges from 19.76 to 24.

16. And / or, The relative permittivity of the simulated human tissue fluid at 22 GHz ranges from 18.37 to 22.

45. And / or, The relative permittivity of the simulated human tissue fluid at 24 GHz ranges from 17.09 to 20.

89. And / or, The relative permittivity of the simulated human tissue fluid at 26 GHz ranges from 15.94 to 19.

48. And / or, The relative permittivity of the simulated human tissue fluid at 28 GHz ranges from 14.90 to 18.

21. And / or, The relative permittivity of the simulated human tissue fluid at 30 GHz ranges from 13.96 to 17.

06.

9. The simulated human tissue fluid according to any one of claims 1 to 7, characterized in that, The conductivity range of the simulated human tissue fluid at 10 GHz includes 7.21 S / m to 8.81 S / m; And / or, The conductivity of the simulated human tissue fluid at 12 GHz ranges from 9.31 S / m to 11.37 S / m. And / or, The conductivity of the simulated human tissue fluid at 14 GHz ranges from 11.42 S / m to 13.96 S / m. And / or, The conductivity of the simulated human tissue fluid at 16 GHz ranges from 13.49 S / m to 16.49 S / m. And / or, The conductivity of the simulated human tissue fluid at 18 GHz ranges from 15.46 S / m to 18.90 S / m. And / or, The conductivity of the simulated human tissue fluid at 20 GHz ranges from 17.30 S / m to 21.14 S / m. And / or, The conductivity range of the simulated human tissue fluid at 22 GHz is 19.00 S / m to 23.22 S / m. And / or, The conductivity of the simulated human tissue fluid at 24 GHz ranges from 20.56 S / m to 25.12 S / m. And / or, The conductivity range of the simulated human tissue fluid at 26 GHz includes 21.97 S / m to 26.85 S / m; And / or, The conductivity range of the simulated human tissue fluid at 28 GHz includes 23.24 S / m to 28.40 S / m; And / or, The conductivity of the simulated human tissue fluid at 30 GHz ranges from 24.39 S / m to 29.81 S / m.

10. A method for preparing simulated human tissue fluid, characterized in that, The simulated human tissue fluid is used to support absorbed power density testing in the frequency range of 10 GHz to 30 GHz, and the preparation method includes the following steps: After adding ionic inorganic salts to water and mixing them evenly, the first aqueous phase mixture is obtained. After uniformly mixing lipids and nonionic surfactants, an oil phase mixture is obtained; The first aqueous phase mixture is added to the oil phase mixture and mixed evenly to obtain the first mixture; Albumin and preservatives are added to the first mixture and mixed evenly to obtain the simulated human tissue fluid.

11. A method for preparing simulated human tissue fluid, characterized in that, The simulated human tissue fluid is used to support absorbed power density testing in the frequency range of 10 GHz to 30 GHz, and the preparation method includes the following steps: After adding ionic inorganic salts and albumin to water and mixing them evenly, a second aqueous phase mixture is obtained. After uniformly mixing lipids and nonionic surfactants, an oil phase mixture is obtained; The second aqueous phase mixture is added to the oil phase mixture and mixed evenly to obtain the second mixture; The preservative is added to the second mixture and mixed evenly to obtain the simulated human tissue fluid.

12. A method for preparing simulated human tissue fluid, characterized in that, The simulated human tissue fluid is used to support absorbed power density testing in the frequency range of 10 GHz to 30 GHz, and the preparation method includes the following steps: After adding ionic inorganic salts, albumin, and preservatives to water and mixing them evenly, a third aqueous phase mixture is obtained. After uniformly mixing lipids and nonionic surfactants, an oil phase mixture is obtained; The third aqueous phase mixture is added to the oil phase mixture and mixed evenly to obtain the simulated human tissue fluid.

Citation Information

Patent Citations

  • Composition simulating the dielectric properties of the human body and use thereof for SAR measurement

    CN104054120A